Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desvenlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desvenlafaxine SCHEMBL34864 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10772550 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3277527 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL10772551 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL2053955 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL623709 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL10491682 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3345158 | 0.98 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306707 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306704 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6644 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2005053703-A1 | COMBINATION THERAPY FOR DEMENTIA, DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2005-06-16 | — | — | WO | claimed |
| EP-1541197-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | B&B Beheer NV (BE) | 2005-06-15 | — | — | EP | claimed |
| WO-2005051297-A2 | COMBINATION DRUG THERAPY TO TREAT OBESITY | THERACOS, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-20040180879-A1 | Novel method of treating vasomotor symptoms | WYETH | 2004-09-16 | — | — | US | claimed |
| US-20040176468-A1 | Enantiomers of O-desmethyl venlafaxine | WYETH (US) | 2004-09-09 | — | — | US | claimed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| US-20030149112-A1 | Enantiomers of O-desmethyl venlafaxine | WYETH | 2003-08-07 | — | — | US | claimed |
| US-20020161055-A1 | Treating, inhibiting or controlling central nervous system disorders | WYETH (FORMERLY KNOWN AS AMERICAN HOME PRODUCTS CORPORATION) | 2002-10-31 | — | — | US | claimed |
| US-20020022662-A1 | Enantiomers of O-desmethyl venlafaxine | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-21 | — | — | US | claimed |
| WO-2000076955-A1 | ENANTIOMERS OF O-DESMETHYL VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-21 | — | — | WO | claimed |